Europe - AMS:CRBN - NL0010583399 - Common Stock
The current stock price of CRBN.AS is 17.665 EUR. In the past month the price increased by 8.07%. In the past year, price decreased by -22.67%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| GIN.DE | GIVAUDAN-REG | 27.2 | 33.81B | ||
| SIKA.DE | SIKA AG-REG | 20.8 | 27.40B | ||
| NZM2.DE | NOVONESIS (NOVOZYMES) B | 76.66 | 21.29B | ||
| DSFIR.AS | DSM-FIRMENICH AG | 76.55 | 19.12B | ||
| BRG.OL | BORREGAARD ASA | 21.42 | 19.02B | ||
| ELK.OL | ELKEM ASA | N/A | 17.06B | ||
| 1COV.DE | COVESTRO AG | N/A | 11.24B | ||
| SY1.DE | SYMRISE AG | 20.23 | 10.26B | ||
| AMC.DE | ALBEMARLE CORP | N/A | 10.09B | ||
| AKZA.AS | AKZO NOBEL N.V. | 19.64 | 9.98B | ||
| SYENS.BR | SYENSQO SA | 18.5 | 7.17B | ||
| EVK.DE | EVONIK INDUSTRIES AG | 8.82 | 6.86B |
Corbion NV engages in the development, production, sale, and distribution of ingredients for food and biochemicals. The company is headquartered in Amsterdam, Noord-Holland and currently employs 2,399 full-time employees. The company operates through two segments: Biobased Ingredients and Biobased Innovations. The Biobased Ingredients segment comprises the Food business division and the Biochemicals business division. The Food business division develops preservation ingredients and microbial spoilage prevention products for the baking, meat, dairy, confectionery and beverage industries, and the Biochemicals business division produces bio-based chemicals derived from renewable resources such as sugar or starch. The Biobased Innovations segment creates new biotechnology business platforms, such aspoly lactic acid (PLA). The firm operates production sites in the United States, Brazil, Spain, the Netherlands and Thailand, and markets its products through a global network of retail offices.
CORBION NV
Piet Heinkade 127
Amsterdam NOORD-HOLLAND NL
Employees: 2407
Phone: 31205906911
Corbion NV engages in the development, production, sale, and distribution of ingredients for food and biochemicals. The company is headquartered in Amsterdam, Noord-Holland and currently employs 2,399 full-time employees. The company operates through two segments: Biobased Ingredients and Biobased Innovations. The Biobased Ingredients segment comprises the Food business division and the Biochemicals business division. The Food business division develops preservation ingredients and microbial spoilage prevention products for the baking, meat, dairy, confectionery and beverage industries, and the Biochemicals business division produces bio-based chemicals derived from renewable resources such as sugar or starch. The Biobased Innovations segment creates new biotechnology business platforms, such aspoly lactic acid (PLA). The firm operates production sites in the United States, Brazil, Spain, the Netherlands and Thailand, and markets its products through a global network of retail offices.
The current stock price of CRBN.AS is 17.665 EUR. The price decreased by -1.53% in the last trading session.
CORBION NV (CRBN.AS) has a dividend yield of 3.65%. The yearly dividend amount is currently 0.71.
CRBN.AS has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
CRBN.AS stock is listed on the Euronext Amsterdam exchange.
ChartMill assigns a technical rating of 4 / 10 to CRBN.AS. When comparing the yearly performance of all stocks, CRBN.AS is a bad performer in the overall market: 87.01% of all stocks are doing better.
ChartMill assigns a fundamental rating of 5 / 10 to CRBN.AS. Both the profitability and the financial health of CRBN.AS get a neutral evaluation. Nothing too spectacular is happening here.
Over the last trailing twelve months CRBN.AS reported a non-GAAP Earnings per Share(EPS) of 1.12. The EPS decreased by -68.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 5.11% | ||
| ROA | 4.55% | ||
| ROE | 9.12% | ||
| Debt/Equity | 0.39 |
14 analysts have analysed CRBN.AS and the average price target is 23.26 EUR. This implies a price increase of 31.65% is expected in the next year compared to the current price of 17.665.
For the next year, analysts expect an EPS growth of 38.56% and a revenue growth -0.98% for CRBN.AS